Drugs / isosulfan blue
isosulfan blue
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | LYMPHAZURIN | — | 1981-07-29 | fda.gov ↗ |
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01771666 | Jul 2012 → Mar 2015 | breast cancer | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT00625625 | Mar 2004 → Nov 2007 | colorectal cancer | Saint John's Cancer Institute | Unknown | No outcome recorded |
| Phase not applicable7 trials | ||||||
| — | NCT01939028 | Jul 2013 → Oct 2016 | endometrial carcinoma | Case Comprehensive Cancer Center | Terminated | No outcome recorded |
| — | NCT01898403 | Jun 2013 → Jun 2014 | melanoma | Stanford University | Completed | No outcome recorded |
| — | NCT01818739 | Mar 2013 → Nov 2016 | endometrial cancer | Ohio State University Comprehensive Cancer Center | Completed | No outcome recorded |
| — | NCT00438477 | Jun 2005 → Aug 2006 | breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| — | NCT00070317 | Jun 2004 → Jan 2013 | cervical adenosquamous carcinoma | Gynecologic Oncology Group | Terminated | No outcome recorded |
| — | NCT00012168 | May 1999 → Jul 2003 | head and neck cancer | NYU Langone Health | Completed | No outcome recorded |
| — | NCT00003186 | Apr 1997 → Mar 2005 | colorectal cancer, metastatic malignant neoplasm | Roswell Park Cancer Institute | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT03927027 Background | Jul 2019 → Nov 2025 overdue | female breast carcinoma | Alliance for Clinical Trials in Oncology | Active not recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00450723 Background | May 2004 → Jan 2011 | breast cancer | University of Miami | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Isosulfan blue | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01898403 ↗ |
| Known as | Lymphazurin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201275 ↗ |
| Known as | NSC-734902 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201275 ↗ |
| Known as | P-1888 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201275 ↗ |
| Known as | P-4125 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201275 ↗ |
| Known as | Sulphan blue 2,5-disulfophenyl isomer | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201275 ↗ |
| Modality | Diagnostic / imaging agent | “In this study we examined the technique of intraoperative hepatic lymphatic mapping with isosulfan blue dye in humans.” PMID 12356141 ↗ Sep 2002 |
| Route | Other | “isosulfan blue is injected subcapsularly around the metastatic lesion” NCT00003186 ↗ |